Skip to main content

AbbVie purchases neuroscience developer Cerevel for $8.7B

By STAT News  
   December 07, 2023

The deal marks the second billion-dollar acquisition by AbbVie in under a week. The company also acquired Immunogen and its ovarian cancer treatment for $10 billion.

Full story

Get the latest on healthcare leadership in your inbox.